BRENETAFUSP
UNII 5GK14JY4JE

Substance Identification & Data

This profile provides standardized clinical and technical data for Brenetafusp, uniquely identified by the FDA Unique Ingredient Identifier (UNII) 5GK14JY4JE.

Technical mappings include the Chemical Abstracts Service (CAS) Registry Number 2736407-54-6 and the RxNorm Concept ID (RxCUI) N/A. Explore the sections below for detailed nomenclature and a complete directory of NDC-listed products containing this ingredient.

FDA UNII Code

5GK14JY4JE

CAS Registry Number

2736407-54-6

RxNorm Concept ID

N/A

Detailed Substance Profile

Preferred Name

BRENETAFUSP

Official standardized name for this substance within the FDA UNII nomenclature system.

NCI Thesaurus

C199026

National Cancer Institute reference terminology for clinical and research data.

INN ID

12532

Sequential identifier assigned via the WHO International Nonproprietary Name program.

USAN ID

MN-104

Identifier assigned by the United States Adopted Names Council.

Substance Type

Brenetafusp

ISO 11238 classification category (e.g., Chemical, Polymer, Protein).

Synonyms and Nomenclature

This section provides a complete list of nomenclature and identifier mappings for Brenetafusp. Identifiers are organized into official regulatory terms, commercial trade names, and technical systematic synonyms used to ensure accurate identification across clinical pharmaceutical databases, regulatory filings, and electronic health records.

FDA Official Name

Brenetafusp

Common Names & Synonyms

BRENETAFUSP [USAN]

Brenetafusp [WHO-DD]

Humanized immunoglobulin anti-(human T-cell surface glycoprotein CD3 epsilon chain) single chain variable fragment (scFv) (1-253) containing the light chain variable (VL) region (1-107), the linker 108GGGGSGGGGSGGGGSGGGGSGGGS131 and the heavy chain variable (VH) region (132-253) fused via the peptide linker 254GGGGS258 to a human T-cell receptor beta chain anti-(human HLAA2 antigen complex with preferentially expressed antigen in melanoma (PRAME) protein) fragment (259-502 in the current sequence) engineered variant (S429>C, C447>A, N461>D), disulfide bridged to a human T cell receptor alpha chain anti-(human HLA-A2 antigen complex with preferentially expressed antigen in melanoma (PRAME) protein) fragment (1-201), engineered variant (T163>C), nonglycosylated, produced in Escherichia coli; humanized monoclonal scFv antibody fusion with human T-cell receptor; CDR source: Mus musculus; antigen: human T-cell surface glycoprotein CD3 epsilon chain, T-cell surface antigen T3/Leu-4 epsilon chain, CD3e (CD3E); type: Fv-kappa scFv; light chain class: kappa; LV germline: Homo sapiens IGKV1-NL1*01; LJ germline: Homo sapiens IGKJ1*01; VL: 1-107; CDR Kabat L1: RASQDIRNYLN (24-34); CDR Kabat L2: YTSRLES (50-56); CDR Kabat L3: QQGNTLPWT (89-97); linker: 108-131; HV germline: Homo sapiens IGHV3-23*04; HJ germline: Homo sapiens IGHJ4*01; VH: 132-253; CDR Kabat H1: GYTMN (162-166); CDR Kabat H2: LINPYKGVSTYNQKFKD (181-197); CDR Kabat H3: SGYYGDSDWYFDV (230-242); linker: 254-258; fusion protein: 259-372; T-cell receptor beta chain (CB) variable domain [TRBV19*01-TRBJ2-7*01]; fusion protein: 373-502 (S429C C447A N461D); T-cell receptor beta chain constant domain [TRBC2*01]; mutation: S429C (disulfide with CA); mutation: C447A (removed disulfide); mutation: N461D (natural variant); fusion protein: 1-115; T-cell receptor alpha chain (CA) variable domain [TRAV26.1*01-TRAJ15*02]; fusion protein: 116-201 (T163C); T-cell receptor alpha chain constant domain [TRAC*01]; mutation: T163C (disulfide with CB)

Immunoglobulin, anti-(human CD3 antigen ε-chain) (human-Mus musculus single-chain Fv fragment VL-((GGGGS)4GGGS)-VH) fusion protein with peptide linker (GGGGS) fusion protein with T-cell receptor β chain [171-cysteine,189-alanine,203-asparatic acid] anti-(human HLA-A2 antigen complex with preferentially expressed antigen of melanoma protein peptide) (human N-terminal fragment), disulfide with T cell receptor α chain [163-cysteine] anti-(human HLA-A2 antigen complex with preferentially expressed antigen of melanoma protein peptide) (human N-terminal fragment)

brenetafusp [INN]